A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

An invaluable resource is being starved to death with no scientific or ethical justification ...

A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a new study.

Immunosuppressive therapy improves pancytopenia in severe aplastic anemia.However, its effects are not long-lasting as evidenced by a modest 2-year EFS rate of just 46%, prompting the need for ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...

Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal ...

YCT-529, a hormone-free male birth control pill, has shown high effectiveness in animals and is now in human trials, marking ...

IgniteData is committed to scaling its EHR-to-EDC automation across global research sites, further advancing clinical trial innovation. Insights gained from each deployment will continue to refine and ...